Objective: To compare treatment effectiveness and persistence in relapsing-remitting
multiple sclerosis patients who initiated rituximab versus glatiramer acetate (GA) or …

Objective: New disease-modifying treatment strategies in multiple sclerosis offer possibilities
for individualised treatment. In this study, we evaluated patient-reported outcome measures …

Background Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS).
More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo …

Importance Comparative real-world effectiveness studies of initial disease-modifying
treatment (DMT) choices for relapsing-remitting multiple sclerosis (RRMS) that include …

Objective To evaluate the efficacy and safety of rituximab for relapsing-remitting multiple
sclerosis. Results Fifteen studies that collectively included 946 patients were selected for the …

Objective: To describe the effects of switching treatment from ongoing first-line injectable
therapies to rituximab on inflammatory activity measured by MRI and levels of CSF …

Objective. To evaluate the efficacy and safety of rituximab in multiple sclerosis in a clinical
practice setting. Methods. Clinical data for all adult patients with multiple sclerosis (MS) …

Background B-cell depleting therapies are highly efficacious in relapsing-remitting multiple
sclerosis but one such therapy, rituximab, is not approved for multiple sclerosis and no …

Importance Therapeutic options for patients with secondary progressive multiple sclerosis
(SPMS) are limited. Objective To analyze disability progression in patients with SPMS …

Background Despite positive results from phase II and observational studies, Rituximab
(RTX) is not currently approved for multiple sclerosis (MS) treatment and can only be used …